Briefing
A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue-Modified Viral HPV DNA
In a prospective single-center cohort of 155 patients, TTMV-guided surveillance first detected 40% of recurrences (median lead time 132 days); overall sensitivity was 73% and was 91% among patients with HPV16 and detectable pretreatment TTMV.
- Design: Evidence level 2
- Assay: Not named in the abstract
Clin Cancer ResPubMed 39715483DOI 10.1158/1078-0432.CCR-24-3053